The University of Tokyo

Kyowa Hakko Kogyo Co., Ltd.

Tak-Circulator Co., Ltd

Takeda Pharmaceutical Company Limited

Tak-Circulator Corporation

Tetsu Akiyama

Yusuke Yamazumi

Kazuyoshi Kofu

Tsutomu Nakamura

Takashi Sekiya

Hiroaki Harada

Shungo Adachi

Takeaki Oda

Susumu Ohwada

Oh Sasaki

Kenichi Tago

A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic or therapeutic agent for disease caused by MEX3B gene expression are provided. This nucleic acid, which inhibits the expression of the MEX3B gene, is an antisense oligonucleotide having a sequence complementary to an oligonucleotide that contains at least 10 contiguous nucleotides in an untranslated region in an exon of the MEX3B gene, or

Nucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression

Provided are a method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and an agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5. A method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 having as the index at least one selected from the group consisting of changes in the expression of the MEX3B gene or MEX3B protein and changes in the function of the MEX3B protein.

Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5

The present invention provides an antibody (anti-BAMBI antibody) which recognizes a polypeptide having the amino acid sequence of SEQ ID No: 1 or a polypeptide having an amino acid sequence containing deletion, substitution or addition of one or more amino acids as compared to the amino acid sequence of SEQ ID No: 1, a method for manufacturing same, a therapeutic agent for colon cancer or liver cancer comprising an anti-BAMBI antibody, a diagnostic agent comprising a primer or probe for detecting the BAMBI gene, and a therapeutic agent for colon cancer or liver cancer comprising a vector which generates BAMBI dsRNA, and the like.

Anti-BAMBI antibody and diagnostic or remedy for colon cancer and liver cancer

The present invention provides a novel &#x3b2;-catenin nuclear localizing protein and DNA encoding the protein. Furthermore, the use of the &#x3b2;-catenin nuclear localizing protein and the DNA encoding the protein provides a diagnostic agent and therapeutic agent for diseases such as cancer which is related to nuclear localization of &#x3b2;-catenin.

&#x3b2;-catenin nuclear localized protein

A protein binding to &#x3b2;-catenin and thus inhibiting the transcriptional activation induced by the formation of a complex of &#x3b2;-catenin with a protein belonging to the TCF/Lef family; a DNA encoding this protein; an antibody recognizing this protein; a therapeutic agent containing the above protein or DNA; and a diagnostic agent containing the above antibody.

Transcriptional activation inhibitory protein

Growing community of inventors

Tokyo, Japan

Tetsu Akiyama